167 related articles for article (PubMed ID: 36943449)
1. A novel combined carbohydrate antigen 19-9 and lymphocyte-to-monocyte ratio score can predict early recurrence of resectable pancreatic ductal adenocarcinoma.
Yugawa K; Maeda T; Nagata S; Sakai A; Taketani K; Yamaguchi S; Konishi K; Hashimoto K
Surg Today; 2023 Oct; 53(10):1199-1208. PubMed ID: 36943449
[TBL] [Abstract][Full Text] [Related]
2. Development of a Biomarker-Based Scoring System Predicting Early Recurrence of Resectable Pancreatic Duct Adenocarcinoma.
Ishido K; Kimura N; Wakiya T; Nagase H; Hara Y; Kanda T; Fujita H; Hakamada K
Ann Surg Oncol; 2022 Feb; 29(2):1281-1293. PubMed ID: 34608555
[TBL] [Abstract][Full Text] [Related]
3. A new scoring system with simple preoperative parameters as predictors of early recurrence of pancreatic ductal adenocarcinoma.
Shimagaki T; Sugimachi K; Mano Y; Tomino T; Onishi E; Nakashima Y; Sugiyama M; Yamamoto M; Morita M; Shimokawa M; Yoshizumi T; Toh Y
PLoS One; 2023; 18(7):e0288033. PubMed ID: 37450554
[TBL] [Abstract][Full Text] [Related]
4. Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center retrospective study.
Matsumoto I; Murakami Y; Shinzeki M; Asari S; Goto T; Tani M; Motoi F; Uemura K; Sho M; Satoi S; Honda G; Yamaue H; Unno M; Akahori T; Kwon AH; Kurata M; Ajiki T; Fukumoto T; Ku Y
Pancreatology; 2015; 15(6):674-80. PubMed ID: 26467797
[TBL] [Abstract][Full Text] [Related]
5. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
[TBL] [Abstract][Full Text] [Related]
6. Preoperative prediction of disease-free survival in pancreatic ductal adenocarcinoma patients after R0 resection using contrast-enhanced CT and CA19-9.
Li D; Peng Q; Wang L; Cai W; Liang M; Liu S; Ma X; Zhao X
Eur Radiol; 2024 Jan; 34(1):509-524. PubMed ID: 37507611
[TBL] [Abstract][Full Text] [Related]
7. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.
Kim NH; Kim HJ
Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):450-455. PubMed ID: 30237091
[TBL] [Abstract][Full Text] [Related]
8. A novel online calculator to predict early recurrence and long-term survival of patients with resectable pancreatic ductal adenocarcinoma after pancreaticoduodenectomy: A multicenter study.
Zhang XP; Gao YX; Xu S; Zhao GD; Hu MG; Tan XL; Zhao ZM; Liu R
Int J Surg; 2022 Oct; 106():106891. PubMed ID: 36165934
[TBL] [Abstract][Full Text] [Related]
9. Does Preoperative Serum Neutrophil to Lymphocyte Ratio (NLR), Platelet to Lymphocyte Ratio (PLR), and Lymphocyte to Monocyte Ratio (LMR) Predict Prognosis Following Radical Surgery for Pancreatic Adenocarcinomas? Results of a Retrospective Study.
Gupta V; Chaudhari V; Shrikhande SV; Bhandare MS
J Gastrointest Cancer; 2022 Sep; 53(3):641-648. PubMed ID: 34406625
[TBL] [Abstract][Full Text] [Related]
10. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study.
Imaoka H; Shimizu Y; Senda Y; Natsume S; Mizuno N; Hara K; Hijioka S; Hieda N; Tajika M; Tanaka T; Ishihara M; Niwa Y; Yamao K
Pancreatology; 2016; 16(4):658-64. PubMed ID: 27178104
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
[TBL] [Abstract][Full Text] [Related]
12. Biological risk based on preoperative serum CA19-9 and histological grade predicts prognosis and improves accuracy of classification in patients with pancreatic ductal adenocarcinoma.
Chang S; Liu Y; Liang Y; Man Q; Li H; Guo Y; Zhao T
Cancer Rep (Hoboken); 2023 Dec; 6(12):e1911. PubMed ID: 37827990
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for early recurrence in patients with pancreatic ductal adenocarcinoma who underwent curative resection.
Murakawa M; Kawahara S; Takahashi D; Kamioka Y; Yamamoto N; Kobayashi S; Ueno M; Morimoto M; Sawazaki S; Tamagawa H; Ohshima T; Yukawa N; Rino Y; Morinaga S
World J Surg Oncol; 2023 Aug; 21(1):263. PubMed ID: 37620940
[TBL] [Abstract][Full Text] [Related]
14. Preoperative Peripheral Blood Lymphocyte-to-Monocyte Ratio Predicts Long-Term Outcome for Patients with Pancreatic Ductal Adenocarcinoma.
Kubota K; Shimizu A; Notake T; Masuo H; Hosoda K; Yasukawa K; Hayashi H; Umemura K; Kamachi A; Goto T; Tomida H; Yamazaki S; Soejima Y
Ann Surg Oncol; 2022 Feb; 29(2):1437-1448. PubMed ID: 34664139
[TBL] [Abstract][Full Text] [Related]
15. Dynamics of Serum CA19-9 in Patients Undergoing Pancreatic Cancer Resection.
van Oosten AF; Groot VP; Dorland G; Burkhart RA; Wolfgang CL; van Santvoort HC; He J; Molenaar IQ; Daamen LA
Ann Surg; 2024 Mar; 279(3):493-500. PubMed ID: 37389896
[TBL] [Abstract][Full Text] [Related]
16. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma.
Gong Y; Song L; Ou L; Lu YY; Huang X; Zeng Q
Iran J Med Sci; 2023 Jul; 48(4):401-413. PubMed ID: 37456201
[TBL] [Abstract][Full Text] [Related]
18. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of preoperative PNI and CA19-9 for pancreatic ductal adenocarcinoma: A multi-institutional retrospective study.
Itoh S; Tsujita E; Fukuzawa K; Sugimachi K; Iguchi T; Ninomiya M; Maeda T; Kajiyama K; Adachi E; Uchiyama H; Utsunomiya T; Ikeda Y; Maekawa S; Toshima T; Harada N; Yoshizumi T; Mori M
Pancreatology; 2021 Oct; 21(7):1356-1363. PubMed ID: 34426076
[TBL] [Abstract][Full Text] [Related]
20. Preoperative carbohydrate antigen 19-9 and standard uptake value of positron emission tomography-computed tomography as prognostic markers in patients with pancreatic ductal adenocarcinoma.
Moon D; Kim H; Han Y; Byun Y; Choi Y; Kang J; Kwon W; Jang JY
J Hepatobiliary Pancreat Sci; 2022 Oct; 29(10):1133-1141. PubMed ID: 33063453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]